Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
16,16-dimethyl-prostaglandin e2
- Development stage
- Phase 1
- Lead developer
- Fate Therapeutics
- Modality
- Small Molecules
- Administration
- Oral, Intravenous
01
Overview
**16,16-dimethyl-prostaglandin e2** is a synthetic analog of prostaglandin E2 consisting of two methyl groups at the 16 position. It acts as an agonist at most EP receptor subtypes and is a potent inhibitor of gastric acid secretion and gastrin release. It has been studied for protective effects on gastric mucosa, prevention and healing of ulcers, preservation of hematopoietic stem cell properties, immunosuppressive effects (such as lessening cyclosporine toxicity), and for its anti-inflammatory actions. Experimentally, it induces cervical ripening and uterine contraction, and protects the gastrointestinal lining. It is considered a research chemical and is not approved for clinical use in humans[1][2][4].
- Brand names
- ProHemaProHema-CB
- Other names
- 16,16-dimethyl-pge216,16-Dimethyl dinoprostone16,16-DimethylprostaglandineE2
02
Targets
HPGD (15-hydroxyprostaglandin dehydrogenase)PTGER3 (Prostaglandin E2 receptor EP3 subtype)PTGER4 (Prostaglandin E2 receptor EP4 subtype)PTGER1 (Prostaglandin E Receptor 1)PTGER2 (Prostaglandin E2 receptor EP2)
Beyond the preview
Go deeper on 16,16-dimethyl-prostaglandin e2.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on 16,16-dimethyl-prostaglandin e2.